{"product_id":"lmat-bcg-matrix","title":"(LMAT) LeMaitre Vascular, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis LeMaitre Vascular, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eArtegraft bovine carotid graft\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eArtegraft bovine carotid graft, acquired by LeMaitre Vascular in 2017, is used in peripheral bypass and dialysis access. In 2025, LeMaitre still points to biologic grafts as a core growth driver, which fits a Stars position in the BCG Matrix. Its role is important because these grafts target high-value vascular procedures with recurring demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eXenoSure biologic patch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eXenoSure biologic patch is LeMaitre Vascular, Inc.'s vascular repair and closure patch, and it fits well with the company’s peripheral vascular focus. The product sits in the growing biologics segment, where demand is supported by surgeons seeking tissue-based repair options. It is a Star because it combines strategic fit with an expanding market, helping LeMaitre build share in a higher-growth category.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVascu-Guard peripheral vascular patch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVascu-Guard is used for vessel repair after surgery, so demand tracks vascular procedure volume. As a biologic patch, it can support premium pricing versus standard synthetics. In LeMaitre Vascular, this kind of niche product helps protect mix and margin in 2025-2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eValvulotome family\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eValvulotome family is a Stars product for LeMaitre Vascular, Inc.: it cuts venous valves for in-situ bypass and serves a well-defined niche in vein bypass surgery. Demand is durable because vascular centers keep using it in routine bypass cases, so it fits a steady, repeat-use profile. That makes it a high-share, low-drama franchise in a specialized market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eIn-situ bypass use case\u003c\/li\u003e\n\u003cli\u003eEstablished vein-bypass niche\u003c\/li\u003e\n\u003cli\u003eRecurring vascular-center demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVascular graft portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLeMaitre Vascular's vascular graft portfolio is a core surgical franchise for bypass and artery replacement, and it fits a Star in the BCG Matrix because it serves broad hospital use with repeat demand. In FY2025, LeMaitre Vascular reported net sales of about $240 million, showing the scale behind this line. The portfolio also supports steady case flow in vascular surgery, where grafts are used across many procedures.\u003c\/p\u003e\n\u003cp\u003eThat matters because repeat purchases come from ongoing surgical volume, not one-time demand. With gross margin near the high-60% range in FY2025, the franchise combines strong use with good economics. It is one of the Company's main engines for growth and cash generation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore bypass and replacement use\u003c\/li\u003e\n\u003cli\u003eMain surgical revenue driver\u003c\/li\u003e\n\u003cli\u003eBroad hospital adoption\u003c\/li\u003e\n\u003cli\u003eRepeat demand supports sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeMaitre’s Star Products Drive Growth and Strong Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLeMaitre Vascular, Inc. Stars are biologic grafts and patches led by Artegraft, XenoSure, and Vascu-Guard, plus the Valvulotome family. In FY2025, Company net sales were about $240 million, and gross margin was near 68%, showing these products can grow and still support strong economics.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar product\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eArtegraft\u003c\/td\u003e\n\u003ctd\u003eBiologic graft growth\u003c\/td\u003e\n\u003ctd\u003eCore demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXenoSure\u003c\/td\u003e\n\u003ctd\u003eExpanding patch segment\u003c\/td\u003e\n\u003ctd\u003eHigh-use repair\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVascu-Guard\u003c\/td\u003e\n\u003ctd\u003ePremium vascular repair\u003c\/td\u003e\n\u003ctd\u003eMix support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eLeMaitre Vascular BCG Matrix shows which units are Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix snapshot for LeMaitre Vascular, Inc. to quickly sort products and spot growth priorities\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for LeMaitre Vascular, Inc., helping decision-makers verify key assumptions fast and trust the analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePruitt F3 carotid shunt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePruitt F3 carotid shunt is a long-established device that temporarily redirects blood flow during carotid endarterectomy, which keeps the brain perfused while the artery is opened. It fits Cash Cows because it is a mature, low-change product with steady hospital demand and recurring use in standard vascular surgery. LeMaitre Vascular can keep harvesting this franchise because the clinical need is stable and the product is already widely known among surgeons.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmbolectomy catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmbolectomy catheters are a core disposable vascular device that removes blood clots from arteries or veins, so every case can mean another sale. In LeMaitre Vascular, Inc.’s BCG Matrix, they fit Cash Cows because repeat hospital use and replacement demand support steady cash flow with low reinvestment. Single-use devices also help protect margins and keep revenue recurring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eThrombectomy catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLeMaitre Vascular's thrombectomy catheters fit Cash Cows because the silicone-balloon design targets venous thrombi in a mature catheter niche, where repeat use matters more than rapid growth. LeMaitre Vascular reported 2024 net sales of $272.4 million and gross margin of 68.6%, showing a stable base that supports these recurring procedural sales. In a slow-growth market, steady hospital demand helps keep catheter volume resilient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePerfusion catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePerfusion catheters fit LeMaitre Vascular, Inc.’s Cash Cows bucket because they infuse blood and fluids into the vasculature as a standard operating-room supply with repeat, established demand. Their growth is usually low, but the installed customer base is sticky, so the line can keep producing steady sales and margins with limited sales spend. In 2025, LeMaitre Vascular reported another year of revenue growth across its vascular portfolio, supporting the cash-generating profile of mature products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStandard OR consumable\u003c\/li\u003e\n\u003cli\u003eRecurring, established demand\u003c\/li\u003e\n\u003cli\u003eLow-growth, cash-generating line\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOcclusion catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcclusion catheters are a mature specialty line that temporarily stops blood flow during vascular procedures, so they fit the Cash Cows box. LeMaitre Vascular sells them through its long-standing vascular channels, which supports repeat orders and steady margins. Public filings do not break out 2025\/2026 occlusion catheter revenue separately, but the product mix benefits from the Company Name’s focused vascular sales base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature, repeat-use specialty catheter\u003c\/li\u003e\n\u003cli\u003eStops blood flow during procedures\u003c\/li\u003e\n\u003cli\u003eDistributed through legacy vascular channels\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeMaitre’s Cash Cows Keep Revenue Steady and Margins Strong\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLeMaitre Vascular’s Cash Cows are mature, repeat-use devices like Pruitt F3 shunts, embolectomy, thrombectomy, perfusion, and occlusion catheters. They sit in stable hospital workflows, so demand is steady and reinvestment stays low. The base is backed by 2024 net sales of $272.4 million and a 68.6% gross margin, with 2025 still showing revenue growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eCash Cow trait\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePruitt F3 shunt\u003c\/td\u003e\n\u003ctd\u003eMature, repeat use\u003c\/td\u003e\n\u003ctd\u003eStandard carotid surgery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCatheters\u003c\/td\u003e\n\u003ctd\u003eRecurring demand\u003c\/td\u003e\n\u003ctd\u003e2024 net sales $272.4m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany\u003c\/td\u003e\n\u003ctd\u003eHigh margin\u003c\/td\u003e\n\u003ctd\u003eGross margin 68.6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eLeMaitre Vascular, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou're previewing the exact LeMaitre Vascular, Inc. BCG Matrix file you'll receive after purchase. The document is fully formatted and ready to use, with no demo content or hidden placeholders. What you see here is the same report you'll download instantly after buying. It’s designed for clear strategic analysis, presentation, and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAngioscopes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAngioscopes are fiberoptic tools used to see inside vessels during vascular surgery, but the use case is narrow and the market is small. In LeMaitre Vascular, Inc.'s BCG matrix, that makes them a Dog: low share, low growth, and far below the scale of grafts and patches, which drive the core franchise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRadiopaque tape\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRadiopaque tape is an ancillary operating-room product used to cross-reference skin and anatomy during procedures, so it supports workflow more than it drives demand on its own. In LeMaitre Vascular, Inc.'s 2025 results, net sales reached about $234 million, up roughly 11% year over year, but this product line likely remains a small, low-growth \"dog\" with limited stand-alone expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy accessory SKUs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy accessory SKUs are Dogs because they are small add-on items around vascular procedures, so they bring low revenue density and little pricing power. In LeMaitre Vascular’s 2025 mix, these items sit far behind core graft and valve lines, and dozens of low-ticket SKUs are hard to scale into a real franchise. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDistributor-only low-volume products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDistributor-only low-volume products sit in Dogs: they are sold through partners, not LeMaitre Vascular, Inc. direct reps, so pricing and placement control is weaker. These items usually move slower than core brands, which can trap cash in low-turn turns and limit margin uplift. LeMaitre Vascular, Inc. does not break out this mix separately in 2025 filings, so the strategic signal is qualitative: keep them only if they protect channel reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartner sold, not direct\u003c\/li\u003e\n\u003cli\u003eLower pricing control\u003c\/li\u003e\n\u003cli\u003eSlower than core brands\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOlder visualization tools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLeMaitre Vascular, Inc. \"Older visualization tools\" fit the Dogs bucket: they support internal vessel viewing, but their clinical use is narrow and highly specialized. Against the Company's 2025 core graft and patch lines, adoption stays limited, so these tools add little scale or growth leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInternal vessel viewing only\u003c\/li\u003e\n\u003cli\u003eNarrow, specialist use case\u003c\/li\u003e\n\u003cli\u003eLow adoption vs. core lines\u003c\/li\u003e\n\u003cli\u003eLikely weak BCG position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeMaitre’s Dog SKUs Stay Small Amid Core Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAngioscopes, radiopaque tape, and legacy accessory SKUs are Dogs for LeMaitre Vascular, Inc.: niche, low-growth items with limited pricing power and little scale versus core grafts and patches. LeMaitre Vascular, Inc. reported 2025 net sales of about $234 million, up about 11% year over year, but these lines still look small and strategically weak.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog item\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAngioscopes\u003c\/td\u003e\n\u003ctd\u003eNarrow use, low scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiopaque tape\u003c\/td\u003e\n\u003ctd\u003eAncillary, low growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy SKUs\u003c\/td\u003e\n\u003ctd\u003eLow revenue density\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAnastoClip AC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAnastoClip AC is a clip-based alternative to sutures for vessel connection, but it sits in the newer closure platform stage, so it is still a Question Mark in the BCG matrix. Adoption is the main test: if surgeons switch, it can gain share; if not, growth stays limited. LeMaitre Vascular must keep pushing training and clinical use to turn it into a larger revenue driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTitanium vessel clips\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTitanium vessel clips are a metal clip technology used to connect vessels, and they stay a small niche versus sutures and grafts in LeMaitre Vascular, Inc.'s BCG view. Adoption depends on surgeon conversion, so growth is tied to training, trust, and repeat use. The segment can stay a question mark until conversion rates and procedure mix improve.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClip applier system\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe clip applier system is a question mark in LeMaitre Vascular, Inc.'s BCG Matrix because it is the delivery tool for the clip platform, but its share is still building. It depends on consumable clips, so growth hinges on surgeon adoption and repeat use. In 2025-2026, it is best treated as a small, high-potential niche with limited scale today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVessel closure systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVessel closure systems are a question mark for LeMaitre Vascular, Inc.: they sit in an alternative closure niche in vascular surgery, but adoption still depends on wider use in the OR. The category is less established than core grafts, which makes growth harder to predict and scale. LeMaitre Vascular, Inc. reported 2025 revenue of about $228 million, but it does not break out vessel-closure sales separately.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAlternative closure niche\u003c\/li\u003e\n\u003cli\u003eOR adoption is the key driver\u003c\/li\u003e\n\u003cli\u003eLess mature than grafts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNew anastomosis accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew anastomosis accessories sit in the Question Marks box: they support vessel joining, but they are still early and likely trail LeMaitre Vascular, Inc.’s legacy implants in scale and cash generation. If procedure use rises, they could move from niche add-ons to a larger growth line, but today their standalone revenue is not disclosed.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdjunct tools for vessel joining\u003c\/li\u003e\n\u003cli\u003eEarly-stage, not core legacy sales\u003c\/li\u003e\n\u003cli\u003eUpside depends on procedure uptake\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeMaitre’s Question Marks: Early-Stage Upside, Adoption Still Key\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eLeMaitre Vascular, Inc.’s Question Marks are small, early-stage vessel-closure and anastomosis tools with limited disclosed revenue and uncertain surgeon adoption. In 2025, LeMaitre Vascular, Inc. reported about $228 million in total revenue, but it did not break out these products separately. The upside is real, but scaling depends on OR use, training, and repeat orders.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2025-2026 view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQuestion Marks\u003c\/td\u003e\n\u003ctd\u003eEarly-stage closure tools\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeMaitre Vascular, Inc. revenue\u003c\/td\u003e\n\u003ctd\u003eAbout $228 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey driver\u003c\/td\u003e\n\u003ctd\u003eSurgeon adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234689523977,"sku":"lmat-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/lmat-bcg-matrix.webp?v=1785723958","url":"https:\/\/dcfanalyst.com\/products\/lmat-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}